Connor Clark & Lunn Investment Management Ltd. Has $42.22 Million Stake in Edwards Lifesciences Corporation $EW

Key Points

• Connor Clark & Lunn boosted its stake in Edwards Lifesciences by 1,017.2% in the third quarter to 542,841 shares worth about $42.22 million (roughly 0.09% of the company).
• Company insiders sold a total of 61,718 shares worth about $5.24 million in the past 90 days—including sizable sales by the VP and CFO—leaving insiders with a 1.29% ownership stake.
• Analysts hold a consensus "Moderate Buy" rating with an average target of $96.14 while the stock trades near $84.62; the latest quarter showed a $0.04 EPS miss but revenue rose 13.3% to $1.57 billion and Q1 2026 EPS guidance is $0.70–$0.76.

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 1,017.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 542,841 shares of the medical research company's stock after acquiring an additional 494,252 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.09% of Edwards Lifesciences worth $42,217,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Level Four Advisory Services LLC raised its position in Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock valued at $257,000 after purchasing an additional 119 shares during the last quarter. Colonial Trust Co SC grew its holdings in shares of Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock worth $2,504,000 after purchasing an additional 120 shares during the last quarter. Howard Capital Management Inc. increased its stake in shares of Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock valued at $322,000 after buying an additional 132 shares during the period. Empirical Finance LLC increased its stake in shares of Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company's stock valued at $1,668,000 after buying an additional 134 shares during the period. Finally, Alpine Bank Wealth Management raised its holdings in Edwards Lifesciences by 10.7% in the 3rd quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company's stock valued at $108,000 after buying an additional 135 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the stock a "hold" rating in a report on Wednesday, February 11th. UBS Group reaffirmed a "neutral" rating and set a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a "buy" rating in a report on Tuesday, January 20th. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Friday, December 5th. Finally, Evercore reaffirmed an "outperform" rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and an average target price of $96.14.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the sale, the vice president owned 21,266 shares in the company, valued at $1,827,387.38. This represents a 34.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,371,239.08. This represents a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 61,718 shares of company stock worth $5,236,281. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 0.6%

Shares of NYSE EW opened at $84.62 on Friday. The company's 50 day moving average price is $82.48 and its 200-day moving average price is $81.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a market capitalization of $49.15 billion, a P/E ratio of 46.24, a price-to-earnings-growth ratio of 2.22 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the company earned $0.59 earnings per share. The company's quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.